Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective
Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1160278/full |
| _version_ | 1797847965213130752 |
|---|---|
| author | Liang Liu Qiong Wang Yan Zhang Jingqi Liang Peilong Liu Hongmou Zhao |
| author_facet | Liang Liu Qiong Wang Yan Zhang Jingqi Liang Peilong Liu Hongmou Zhao |
| author_sort | Liang Liu |
| collection | DOAJ |
| description | Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development of an effective prevention and treatment strategy for CN is still a great challenge. Of note, recent studies providing an insight into the molecular mechanisms of bone metabolism and homeostasis have propelled development of novel CN therapeutic strategies. Therefore, this review aims to shed light on the pathogenesis, diagnosis, and treatment of CN. In particular, we highlight the eminent role of the osteoprotegerin (OPG)-receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) system in the development of CN. Furthermore, we summarize and discuss the diagnostic biomarkers of CN as well as the potential pharmacological mechanisms of current treatment regimens from the perspective of bone metabolism. We believe that this review will enhance the current state of knowledge on the diagnosis, prevention, and therapeutic efficacy of CN. |
| first_indexed | 2024-04-09T18:20:50Z |
| format | Article |
| id | doaj.art-43048aae87d044a882b73429d35c9717 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-09T18:20:50Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-43048aae87d044a882b73429d35c97172023-04-12T07:52:16ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-04-011410.3389/fphar.2023.11602781160278Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspectiveLiang LiuQiong WangYan ZhangJingqi LiangPeilong LiuHongmou ZhaoCharcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development of an effective prevention and treatment strategy for CN is still a great challenge. Of note, recent studies providing an insight into the molecular mechanisms of bone metabolism and homeostasis have propelled development of novel CN therapeutic strategies. Therefore, this review aims to shed light on the pathogenesis, diagnosis, and treatment of CN. In particular, we highlight the eminent role of the osteoprotegerin (OPG)-receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) system in the development of CN. Furthermore, we summarize and discuss the diagnostic biomarkers of CN as well as the potential pharmacological mechanisms of current treatment regimens from the perspective of bone metabolism. We believe that this review will enhance the current state of knowledge on the diagnosis, prevention, and therapeutic efficacy of CN.https://www.frontiersin.org/articles/10.3389/fphar.2023.1160278/fullbone metabolismCharcot neuroarthropathypharmacologyRANKLtherapeutics |
| spellingShingle | Liang Liu Qiong Wang Yan Zhang Jingqi Liang Peilong Liu Hongmou Zhao Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective Frontiers in Pharmacology bone metabolism Charcot neuroarthropathy pharmacology RANKL therapeutics |
| title | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
| title_full | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
| title_fullStr | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
| title_full_unstemmed | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
| title_short | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
| title_sort | therapeutics of charcot neuroarthropathy and pharmacological mechanisms a bone metabolism perspective |
| topic | bone metabolism Charcot neuroarthropathy pharmacology RANKL therapeutics |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1160278/full |
| work_keys_str_mv | AT liangliu therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT qiongwang therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT yanzhang therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT jingqiliang therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT peilongliu therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT hongmouzhao therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective |